CYTEK BIOSCIENCES, INC.

Industry’s First End-to-End Flow Cytometry Platform Covering Panel Design Through Data Analysis FREMONT, Calif., September 23, 2026 – Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the expansion of its Cytek® Cloud digital ecosystem with a new Cloud Analysis tool, establishing the industry’s first end-to-end platform that integrates the entire flow cytometry workflow from panel design to data analysis into one system. Cytek Cloud is built by the scientists and engineers behind Cytek Full Spectrum Profiling™ (FSP®) technology and gives researchers a consistent experience from experiment planning through data analysis while reducing the need to move between systems or recreate work along the way. Historically, moving from data acquisition to analysis has meant transferring data to a separate platform and recreating worksheets, plots and gates. Cytek’s Cloud Analysis tool changes that workflow by preserving experimental data and allowing researchers to import it directly from SpectroFlo® desktop software, so they can pick up their analysis where they left off. The cloud-based environment also provides online data storage, giving researchers access to their data and analysis workflows from virtually anywhere, on a Mac or PC. With more than 28,000 users and double-digit year-over-year user growth, Cytek Cloud has solidified its place as a crucial resource for researchers since its introduction in 2022. The platform supports full spectrum flow cytometry research from panel design and experiment setup through data acquisition and now data analysis. The Cytek Cloud Digital Ecosystem Cytek Cloud currently includes a suite of integrated online tools, including Full Spectrum Viewer, Panel Builder, Experiment Builder and Cloud Analysis, designed to support workflows on Cytek Northern Lights™, Cytek Aurora®, Cytek Aurora® Evo and Cytek Aurora® CS systems. Panel Builder helps researchers design spectral panels while taking into account factors such as antigen density, marker expression and reagent availability. Researchers can search and work from pre-designed panels and Optimized Multicolor Immunofluorescence Panels (OMIPs), as well as build and share their own panels. Cytek Cloud also features the AI-powered SpectroPanel™ tool, which u

Complementary Technologies Deliver an Integrated, End-to-End Clinical Flow Cytometry Workflow for Laboratories Across Europe FREMONT, Calif., and HAMBURG, Germany – September 9, 2026 – Sysmex Europe SE, a leader in diagnostic and healthcare solutions, and Cytek Biosciences, Inc. (Nasdaq: CTKB), a leader in spectral flow cytometry technology, today announced a strategic collaboration across over a dozen European countries to enhance clinical flow cytometry workflows and expand access to innovative diagnostic solutions. The collaboration brings together the expertise and technologies of both companies to provide clinical laboratories with a broader portfolio of flow cytometry technologies that improve workflow efficiency, standardization and advanced clinical capabilities. Together, Sysmex and Cytek will offer integrated, end-to-end solutions that support laboratories from sample preparation through advanced multi-color analysis. Clinical flow laboratories face growing demand for faster, more standardized testing while managing increasingly complex diagnostic requirements. Through this collaboration, Sysmex's established clinical flow cytometry portfolio – including the XF-1600 flow cytometer for routine testing and the PS-10 automated sample preparation system – will be complemented by Cytek's Northern Lights™-CLC spectral flow cytometer. The complementary offering enables laboratories to perform advanced multi-color applications required for leukemia and lymphoma as well as measurable residual disease assessment, creating a comprehensive solution for specialized clinical flow cytometry laboratories. “By combining our expertise in laboratory au

FREMONT, Calif., September 3, 2026 – As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced solutions at two leading clinical cytometry events this fall: the European Society for Clinical Cell Analysis (ESCCA) 2026 Conference and ICCS 2026, the 41st Annual International Clinical Cytometry Meeting &amp; Course. Set apart from traditional flow cytometry approaches, Cytek’s distinctive Full Spectrum Profiling™ (FSP®) technology is helping to expand the possibilities of cell analysis across research and clinical applications. By capturing the full spectrum of fluorescent signals, Cytek’s spectral technology enables laboratories to analyze more complex panels, streamline workflows, and extract deeper insights from each sample. With more than 4,200 peer-reviewed publications citing the use of Cytek’s FSP systems, the technology continues to support advances across cell biology, immunology, oncology, and clinical research. ESCCA ESCCA is an important forum for education and scientific exchange in basic, translational, and clinical applications of cytometry, particularly in hematology, immunology, cancer, and cell biology. ESCCA 2026 will be held in Salzburg, Austria, from September 9 through September 12 and will convene clinicians, researchers, and other experts from around the world. At the conference, Cytek will showcase its full range of cell analysis solutions at Booth PL2, demonstrating how spectral flow cytometry can support increasingly sophisticated clinical applications while helping laboratories improve efficiency and data quality. Cytek will also host an Industrial Partner Presentation on Friday, September 11, at 12:15 p.m., titled “Do We Really Need 40 Colors? Rethinking Spectral Cytometry for Routine Diagnostics and MRD Monitoring.” The presentation will be led by Mikael Roussel, M.D., Ph.D., Hematology Laboratory &amp; INSERM U1236, University Hospital Pontchaillou, and will examine the role of spectral cytometry in routine diagnostics and minimal residual disease (MRD) monitoring. ICCS <span style="font-family: Aria